CD14 -159C>T — The Innate Immune Dimmer Switch
CD14 is the first responder to bacterial invasion. Expressed on the surface of
monocytes and macrophages11 monocytes and macrophages
the frontline phagocytic cells of innate immunity,
CD14 acts as a co-receptor that binds lipopolysaccharide (LPS) — the potent
endotoxin coating the outer membrane of every gram-negative bacterium in your gut,
on your skin, and in the environment. Once CD14 captures LPS, it hands it off to
TLR4/MD-222 TLR4/MD-2
Toll-like receptor 4, the signal-transducing partner that fires the
NF-κB inflammatory cascade, triggering
cytokine release and the full inflammatory response to bacterial threats.
The -159C>T promoter variant (rs2569190, also reported as -260C>T depending on the
transcription start site used) is one of the most studied functional SNPs in
immunogenetics. It sits in a GC-box element in the CD14 promoter33 GC-box element in the CD14 promoter
a transcription
factor binding site ~159 base pairs upstream of the coding sequence
and changes how much CD14 protein your immune cells produce. The variant is notable
for driving one of the clearest gene-environment interactions in all of allergy
research.
The Mechanism
The T allele (reported as A on the plus strand in genome files; the gene is on the
minus strand of chromosome 5) is associated with a functional impact on CD14
transcription44 functional impact on CD14
transcription
In vivo chromatin immunoprecipitation shows twice as much RNA
polymerase II recruited to the T-allele haplotype, indicating stronger transcription
initiation, though allele-specific transcript quantification finds similar mRNA
output between haplotypes.
The net result is that
TT homozygotes have significantly higher circulating soluble CD14 (sCD14)55 TT homozygotes have significantly higher circulating soluble CD14 (sCD14)
sCD14
is shed from monocyte surfaces and acts as a soluble pattern-recognition molecule
extending LPS detection to cells that don't express membrane CD14.
CC homozygotes produce less sCD14 and have a more muted basal response to
bacterial endotoxin.
This expression difference creates the paradox at the heart of the hygiene hypothesis: higher CD14 = more efficient LPS detection = stronger Th1 skewing = protection against allergic sensitization — but only when microbial exposure is high enough to exploit that capacity. In environments with low endotoxin load (urban living, formula feeding, no farm exposure), the T allele's higher CD14 expression may paradoxically drive heightened allergic responses by amplifying immune reactivity without the Th1-steering effect that requires persistent bacterial stimulation.
The Evidence
Baldini et al. 199966 Baldini et al. 1999
Original discovery in 481 children: TT homozygotes
had significantly higher sCD14 and lower total IgE among skin-test-positive
children (p=0.004) established that
the T allele of CD14/-159 is the higher-expression variant and reduces IgE-mediated
sensitization — but only in atopic children, implying a gene-environment gate.
The gene-environment interaction was definitively demonstrated by
Simpson A et al. 200677 Simpson A et al. 2006
Study of 442 Manchester children showing opposite CD14 allele
effects depending on farming exposure.
In children with low endotoxin exposure, the C allele (GG genotype on plus strand)
was the allergy risk genotype. In children with high endotoxin exposure (farm
families), the T allele (AA on plus strand) became the risk genotype. The crossover
was replicated across four independent populations (rural Europe, Manchester, Detroit,
Barbados), with the most dramatic crossover effects seen in the high-contrast exposure
settings.
A meta-analysis of 23 studies including 4,780 cases and 5,650 controls88 A meta-analysis of 23 studies including 4,780 cases and 5,650 controls
BMC Medical
Genetics 2011, PMID 21745379 found that
when restricted to homogeneous atopic asthma phenotypes, the T allele is protective:
TT vs CC OR = 0.67 (95% CI 0.54-0.84) and CT vs CC OR = 0.80 (95% CI 0.66-0.95),
consistent with a codominant protective effect — in populations without stratification
by endotoxin exposure.
Kerkhof et al. 201299 Kerkhof et al. 2012
JACI, PMID 21996339
pooled three allergy-prevention intervention cohorts and showed the genotype determines
whether reducing microbial exposure in infancy helps or harms: interventions that
decreased indoor allergen/endotoxin exposure were protective in CC children but
increased atopy in TT children — a striking pharmacogenomic-style genotype-determines-
direction effect.
For infectious disease, the T allele (AA genotype) consistently shows survival advantage.
Mansur et al. 20151010 Mansur et al. 2015
Prospective cohort of 417 sepsis patients, PMID 26020644
found that C-allele carriers had 23% 30-day mortality vs 13% for TT homozygotes, with
the C allele remaining a significant independent covariate in multivariate Cox regression
(HR 2.11, 95% CI 1.08-4.12, p=0.028). Higher sCD14 from the T allele appears to
improve LPS clearance and dampen the cytokine storm cascade driving organ failure.
Conversely, for SARS-CoV-2, Pati et al. 20211111 Pati et al. 2021
JID, PMID 33822099
found the T allele (higher CD14 expression) correlates with higher COVID-19 infection
rates and mortality across European countries (r=0.57 and r=0.61 respectively), while
the CC genotype was protective against severe SARS. This is consistent with the
hygiene-hypothesis model: high CD14 may amplify inflammatory responses to novel
viral-associated LPS signals or drive excessive innate immune activation.
Practical Actions
The actionable takeaway from this literature is not "which allele is good" — both have context-dependent advantages — but rather understanding how your genotype interacts with your microbial environment. GG (CC in papers) carriers benefit most from increasing microbial diversity; their lower-expression CD14 means they need richer bacterial stimulation to drive appropriate Th1 immune development and LPS tolerance. AA (TT) carriers already produce abundant CD14 and may be more sensitive to both high endotoxin environments and novel inflammatory triggers. For sepsis prevention, AA carriers appear inherently more resilient. For allergy prevention in low-endotoxin environments, GG carriers are at higher baseline risk and benefit most from microbial exposure strategies.
Probiotic strain selection matters for this SNP. Gram-negative probiotics and fermented foods containing LPS-like molecules (e.g. Bifidobacterium species, spore-forming Firmicutes) stimulate the CD14/TLR4 axis differently than gram-positive species with lipoteichoic acid. For GG carriers building Th1 tolerance, gram-negative-rich fermented foods provide endotoxin-tolerizing stimulation without excessive inflammatory drive.
Interactions
The most important interaction is with TLR4 (rs4986790, Asp299Gly)1212 TLR4 (rs4986790, Asp299Gly)
TLR4 is the
downstream signal transducer for LPS delivered by CD14.
CD14 captures LPS and hands it to TLR4; variants in both genes affect the same
LPS-sensing pathway and may have compounded effects. Individuals with low-CD14
expression (GG at rs2569190) combined with blunted TLR4 signaling (Asp299Gly at
rs4986790) would have doubly impaired LPS recognition.
IL-1β (rs16944)1313 IL-1β (rs16944)
a downstream cytokine produced after TLR4 activation
and [TNF-α (rs1800629) | another key effector cytokine in the LPS response]
polymorphisms modify the magnitude of the downstream inflammatory response once
CD14-mediated LPS recognition occurs. Combined low-CD14 (GG) with high-TNF
(rs1800629 AA) may create discordant signaling — poor initial sensing but exaggerated
response once threshold is crossed.
For the allergy interaction: the hygiene hypothesis gene-environment effect is most pronounced for TLR2 and TLR4 co-variants. Studies suggest that the farming protective effect on allergy operates through the CD14-TLR4-IL-12 axis, and variants in any of these genes modulate how robustly farm environments suppress IgE responses.